BradleyJamesSumrowMD

Research • Cambridge, MA

Executive Medical Director, Immuno-oncology Clinical Research/Development

Join to view full profile

Dr. Sumrow is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Sumrow's full profile

Already have an account?

Office
840 Memorial
Cambridge, MA 02139

Summary

Dr. Bradley J. Sumrow is an oncology clinical research & development specialist based in Cambridge, MA, with a background in anesthesiology from his residency at University of North Carolina Hospitals. He graduated from the University of North Carolina at Chapel Hill School of Medicine in 2010. Dr. Sumrow has published work on PD-1-guided CTLA-4 blocking bispecific DART molecules, which has been cited 39 times. He is involved in multiple clinical trials, including studies on XMT-2056 (HER2-directed STING agonist ADC), tebotelimab (PD-1 x LAG3 DART), mivavotinib, sapanisertib, and combination treatments with enoblituzumab for various types of cancer.

Education & Training

University of North Carolina HospitalsResidency, Anesthesiology, 2010 - 2014
University of North Carolina at Chapel Hill School of MedicineClass of 2010

Certifications & Licensure

NC State Medical License 2015 - 2026

Clinical Trials

MGD019 DART® Protein in Unresectable/Metastatic Cancer Start of enrollment: 2018 Dec 12
Active, not recruiting
Phase 1
A Study of Sapanisertib in Relapsed/Refractory NFE2L2-Mutated and Wild-Type Squamous Non-Small Cell Lung Cancer Start of enrollment: 2022 Apr 15
Terminated
Phase 2
A Study of XMT-2056 in Advanced/Recurrent Solid Tumors That Express HER2 Start of enrollment: 2023 Jan 24
Recruiting
Phase 1
Enoblituzumab Plus Retifanlimab or Tebotelimab in Head and Neck Cancer Start of enrollment: 2021 Mar 17
Terminated
Phase 2
A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms Start of enrollment: 2017 Aug 18
Completed
Phase 1
Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer Start of enrollment: 2019 Sep 30
Active, not recruiting
Phase 2, Phase 3
Enoblituzumab Plus MGA012 or MGD013 in Squamous Cell Carcinoma of the Head and Neck Start of enrollment: 2019 Oct 01
Withdrawn
Phase 2, Phase 3
Study of Mivavotinib (CB-659) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Start of enrollment: 2022 Jun 23
Terminated
Phase 2
Join now to see all

Publications & Presentations

PubMed

35 citations
The PD-1- and LAG-3-targeting bispecific molecule tebotelimab in solid tumors and hematologic cancers: a phase 1 trial.
Jason J Luke, Manish R Patel, George R Blumenschein, Erika Hamilton, Bartosz Chmielowski
Nature Medicine. 2023-11-01
39 citations
Development and Preliminary Clinical Activity of PD-1-Guided CTLA-4 Blocking Bispecific DART Molecule.
Alexey Berezhnoy, Bradley James Sumrow, Kurt Stahl, Kalpana Shah, Daorong Liu
Cell Reports. Medicine. 2020-12-22